Denali therapeutics press release. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights. Jan 29, 2026 · The Investor Relations website contains information about Denali Therapeutics's business for stockholders, potential investors, and financial analysts. Aug 11, 2025 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics and commercial potential; statements made by Denali's Chief Executive Officer; plans, timelines, and expectations relating to DNL310, including the PDUFA target Jan 8, 2025 · SOUTH SAN FRANCISCO, Calif. Nov 6, 2025 · The Investor Relations website contains information about Denali Therapeutics's business for stockholders, potential investors, and financial analysts. (Nasdaq: DNLI) today announced that the U. , May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. investors. Denali to host Investor Day on December 4, 2025 SOUTH SAN FRANCISCO, Calif. 6 days ago · Tividenofusp alfa is a next-generation enzyme replacement therapy (ERT), by Denali Therapeutics, for the treatment of patients with mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. (NASDAQ: DNLI), today announced that the U. Denali Therapeutics Inc (FRA:4DN) stock price, GURU trades, performance, financial stability, valuations, and filing info from GuruFocus. May 6, 2025 · SOUTH SAN FRANCISCO, Calif. Food and Drug Administration has accepted for review the Biologics License Application seeking accelerated approval for tividenofusp alfa Dec 9, 2025 · SOUTH SAN FRANCISCO, Calif. The FDA has set a PDUFA target action date of January 5, 2026. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Food and May 6, 2025 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations regarding Denali’s TV platform and its therapeutics and Jan 13, 2025 · Denali Therapeutics has pioneered and is delivering a new class of therapeutics using its TransportVehicle TM (TV) platform to enable and transform treatment for people living with rare and common Feb 27, 2025 · SOUTH SAN FRANCISCO, Calif. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock 4 days ago · Stay up to date with all latest press releases from Denali Therapeutics Inc. , Jan. Feb 5, 2026 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali Therapeutics Inc. About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. Feb 1, 2024 · --Denali Therapeutics Inc. (DNLI) stock news and headlines to help you in your trading and investing decisions. 49 per pre Nov 6, 2025 · Read Press Release for Denali Therapeutics (DNLI) published on Nov. Food and Drug Administration (FDA) has granted Breakthrough Jan 13, 2025 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali Therapeutics Inc. Jan 6, 2026 · SOUTH SAN FRANCISCO, Calif. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. Denali Therapeutics Announces $500 million Private Placement Equity Financing Denali Therapeutics Inc. , Nov. , Dec. 3 days ago · Press Release Distributed by ABNewswire. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Bioz Stars score: 90/100, based on 1 PubMed citations. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative Nov 6, 2025 · This is a paid press release. ("Denali" or the "Company"); Denali's business strategy and business plans, including expected key milestones for Denali's therapeutic Find the latest press releases and official documents published by Denali Therapeutics Inc. com investors. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations regarding Denali’s TV platform and its therapeutics and commercial potential; statements made by Denali’s Chief Executive Officer; plans, timelines, and expectations relating to DNL310, including Jul 7, 2025 · SOUTH SAN FRANCISCO, Calif. 50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17. Deep-dive analysis for managed care leader 5 days ago · R1 Therapeutics launches with oversubscribed $77. "As leaders in pioneering a new class of therapeutics that cross the blood-brain Jan 9, 2025 · Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway SOUTH SAN FRANCISCO, Calif. The company reports alignment with CDER on the BLA data package, including using cerebrospinal fluid heparan Hello, and welcome to the Denali Therapeutics webinar on interim data from our Phase I/II study of DNL310 in patients with Hunter syndrome or MPS II. , March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, today announced its launch with an oversubscribed $77. The FDA granted it Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations and a Priority Review. Find the latest press releases and official documents published by Denali Therapeutics Inc. The submission has been received by the FDA's Center for Drug Evaluation and Research (CDER). , Feb. , July 07, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Apr 12, 2023 · About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases. Jul 7, 2025 · --Denali Therapeutics Inc. “The completion of our BLA submission for tividenofusp alfa represents a pivotal SOUTH SAN FRANCISCO, Calif. com To view the original version on ABNewswire visit: Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals This article contains syndicated content. today announced that the U. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative Jan 8, 2024 · Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readinessAdvance broad clinical-stage portfolio of seven therapeutic product candidates across investors. The Key Amyotrophic Lateral Sclerosis Companies in the market include – Amylyx Pharmaceuticals, Sanofi, Brainstorm Cell Therapeutics, AI Therapeutics, Ionis, Biogen, Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics 3 days ago · A newly presented analysis from the phase 2b LUMA study (NCT05348785) of BIIB122/DNL151 (Biogen/Denali Therapeutics), an investigational LRRK inhibitor, demonstrated that multiple sensor-derived measures from Konectom’s smartphone-based typing test showed high reliability in patients with Parkinson disease (PD). Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding plans, timelines, and expectations related to Denali's TransportVehicle™ (TV) platform and its therapeutic and commercial potential; plans May 7, 2025 · SOUTH SAN FRANCISCO, Calif. 5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Structured Review Denali Therapeuticsformation of mckinley (denali) mountainsFormation Of Mckinley (Denali) Mountains, supplied by Denali Therapeutics, used in various techniques. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease Mar 10, 2026 · Denali Therapeutics Inc. I am Laura Hansen, Vice President of Investor Relations, and I'd like to thank you for joining our webcast today. 06, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (“Denali” or the “Company”); Denali’s business strategy and business plans, including expected key milestones for Denali's May 31, 2022 · Biogen Safe Harbor This press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential benefits and results that may be achieved through Biogen’s collaboration with Denali; the potential benefits, safety and Apr 2, 2025 · Denali Therapeutics (NASDAQ: DNLI) has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa to treat Hunter syndrome (MPS II). (“Denali” or the “Company”); Denali’s business strategy and business plans, including expected key milestones for Denali's Jul 8, 2025 · This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. (DNLI). Sep 3, 2024 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's plans, timelines, and expectations related to tividenofusp alfa Jul 7, 2025 · Denali Therapeutics (NASDAQ:DNLI) announced that the FDA has accepted and granted Priority Review for their Biologics License Application (BLA) for tividenofusp alfa, a potential treatment for Hunter syndrome (MPS II). (NASDAQ: DNLI), today announced key anticipated milestones and priorities for 2026 across its portfolio of investigational therapies for neurodegenerative diseases, lysosomal storage disorders and other serious diseases. 6, 2025 - Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights Jan 13, 2025 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali Therapeutics Inc. com Jan 14, 2025 · Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17. “The FDA’s priority review of our BLA for tividenofusp alfa and alignment on an Get the latest Denali Therapeutics Inc. Jan 8, 2024 · --Denali Therapeutics Inc. , Aug. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided Jan 9, 2023 · This is a paid press release. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and Feb 27, 2024 · This is a paid press release. 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc Nov 7, 2023 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations regarding Denali’s TV technology platform, including the Find the latest press releases and official documents published by Denali Therapeutics Inc. 's ("Denali" or the "Company") business strategy and business plans, including expected key milestones for Denali's therapeutic portfolio in 2026 and beyond and Denali’s ability to execute on its Aug 11, 2025 · This is a paid press release. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative and Sep 3, 2024 · The TV platform has been clinically validated and three TV-enabled programs are currently in clinical development. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI) Leerink Global Healthcare Conference 2026 March 9, 2026 3:40 PM EDTCompany ParticipantsRyan Watts - Co-Founder, President, REDWOOD CITY, Calif. Feb 26, 2026 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali’s TransportVehicle™ (TV) platform and its therapeutics and commercial potential; statements regarding Denali's business strategy and business plans, including expected key milestones for Denali Denali Therapeutics Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided Jan 13, 2025 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali Therapeutics Inc. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Please note that the press release we issued earlier today and the slide deck for this webcast are available in the Investors Aug 14, 2024 · --Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights. Aug 1, 2024 · --Denali Therapeutics Inc. S. We discover, develop and deliver medicines for people living with serious diseases. Aug 11, 2025 · Denali Therapeutics 8-K Denali Therapeutics Press release on Q2 2025 financial results Denali Therapeutics Q2 2025 Highlights FAQ Why is this newsworthy? The acceptance of the Biologics License Application (BLA) for tividenofusp alfa for priority review by the FDA, with a PDUFA target action date of January 5, 2026, is a critical regulatory Apr 2, 2025 · Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. 6 days ago · Prime Therapeutics Report Spring 2026: specialty pharmacy and managed care insights on therapeutic pipeline, payer management and pharmacy benefit strategy. com Aug 12, 2025 · SOUTH SAN FRANCISCO, Calif. Food and Drug Administration (FDA) has accepted for review the Nov 6, 2024 · SOUTH SAN FRANCISCO, Calif. . Feb 27, 2024 · Neurodegenerative disease drugmaker Denali Therapeutics announced Tuesday it is raising an expected $500 million through a private financing deal with existing investors. Tividenofusp alfa represents a significant advancement in enzyme replacement therapy, being the first in nearly 20 Dec 5, 2022 · The design phase for entry of DNL343 into a Phase 2/3 trial in the HEALEY ALS Platform Trial is underway SOUTH SAN FRANCISCO, Calif. denalitherapeutics. on MarketScreener. Contact the press release distributor directly with any inquiries. Through the deal, the company will sell over 3 million shares of its common stock at $17. 07 apiece and issue warrants for more Nov 7, 2024 · SOUTH SAN FRANCISCO, Calif. flqaw wtajm awchli lyy piend kofr vejzwzk keichdq tzatam vkg